Biotechnology firms raised more than $1 billion through 56 deals in the first quarter of 2007, according to Burrill & Company.

The number of deals was double that in the first quarter of 2006 and a 33 percent jump over the fourth quarter, Burrill reported.

Investments averaged $21 million, a figure that Burrill said “has held steady for several quarters.”

Selected financings included:

  • EUSA Pharma, $175 million
  • Targanta Therapeutics, $70 million
  • Ception Therapeutics, $63 million
  • Omeros Corp, $55 million
  • Phenomix Corp, $50 million
  • Microbia Inc, $50 million
  • Intarcia Therapeutics, $50 million
  • MAP Pharmaceuticals, $50 million
  • Cylene Pharmaceuticals Inc, $44 million
  • TransOral Pharmaceuticals, $40 million
  • Fluidigm Corporation, $37 million
  • Epiphany Biosciences, $36 million
  • Sequoia Pharmaceuticals, $35 million
  • Proacta Inc, $35 million
  • BiPar Sciences, $35 million

Burrill & Company, which is based in San Francisco, focuses on life sciences, venture capital, merchant banking and media.